Literature DB >> 14514947

Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

K M Fong1, Y Sekido, A F Gazdar, J D Minna.   

Abstract

It has been hypothesised that clinically evident lung cancers have accumulated many different genetic or epigenetic abnormalities in oncogenes and/or tumour suppressor genes. This notion has important clinical ramifications. Recent developments in our knowledge of the molecular biology of lung cancer are reviewed, with particular reference to genetic abnormalities in tumour suppressor gene inactivation and overactivity of growth promoting oncogenes. These changes lead to the "hallmarks of lung cancer". These hallmarks are the new rational targets for early detection, prevention, and treatment of lung cancer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14514947      PMCID： PMC1746489          DOI： 10.1136/thorax.58.10.892

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  152 in total

1.  Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence.

Authors:  C A Angeletti; M Lucchi; G Fontanini; A Mussi; A Chella; A Ribechini; S Vignati; G Bevilacqua
Journal:  Cancer       Date:  1996-08-01       Impact factor: 6.860

2.  Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications.

Authors:  P T Cagle; A K el-Naggar; H J Xu; S X Hu; W F Benedict
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

3.  Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.

Authors:  S Rodenhuis; L Boerrigter; B Top; R J Slebos; W J Mooi; L van't Veer; N van Zandwijk
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

4.  Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.

Authors:  H Dosaka-Akita; S X Hu; M Fujino; M Harada; I Kinoshita; H J Xu; N Kuzumaki; Y Kawakami; W F Benedict
Journal:  Cancer       Date:  1997-04-01       Impact factor: 6.860

5.  Bombesin receptor structure and expression in human lung carcinoma cell lines.

Authors:  Z Fathi; J W Way; M H Corjay; J Viallet; E A Sausville; J F Battey
Journal:  J Cell Biochem Suppl       Date:  1996

6.  Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.

Authors:  E Brambilla; A Negoescu; S Gazzeri; S Lantuejoul; D Moro; C Brambilla; J L Coll
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

7.  Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung cancer.

Authors:  X Ou; S Campau; R Slusher; R K Jasti; M Mabry; G P Kalemkerian
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

8.  Differences in lung cancer risk between men and women: examination of the evidence.

Authors:  E A Zang; E L Wynder
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

9.  Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression.

Authors:  G Fontanini; S Vignati; M Lucchi; A Mussi; A Calcinai; L Boldrini; S Chiné; V Silvestri; C A Angeletti; F Basolo; G Bevilacqua
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.

Authors:  P Pfeiffer; P P Clausen; K Andersen; C Rose
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640
View more
  29 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

2.  Differential expression of VASP in normal lung tissue and lung adenocarcinomas.

Authors:  L Dertsiz; G Ozbilim; Y Kayisli; G A Gokhan; A Demircan; U A Kayisli
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

3.  CUGBP1 promotes cell proliferation and suppresses apoptosis via down-regulating C/EBPα in human non-small cell lung cancers.

Authors:  Haijiao Lu; Zhuang Yu; Shihai Liu; Lianhua Cui; Xiaozheng Chen; Ruyong Yao
Journal:  Med Oncol       Date:  2015-02-21       Impact factor: 3.064

4.  H-REV107-1 stimulates growth in non-small cell lung carcinomas via the activation of mitogenic signaling.

Authors:  Irina Nazarenko; Glen Kristiansen; Sabine Fonfara; Raphaela Guenther; Cornelia Gieseler; Wolfgang Kemmner; Reinhold Schafer; Iver Petersen; Christine Sers
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

5.  High speed digital protein interaction analysis using microfluidic single molecule detection system.

Authors:  Chao-Kai Chou; Nan Jing; Hirohito Yamaguchi; Pei-Hsiang Tsou; Heng-Huan Lee; Chun-Te Chen; Ying-Nai Wang; Sungmin Hong; Chin Su; Jun Kameoka; Mien-Chie Hung
Journal:  Lab Chip       Date:  2010-05-24       Impact factor: 6.799

6.  EMX2 is epigenetically silenced and suppresses growth in human lung cancer.

Authors:  J Okamoto; T Hirata; Z Chen; H-M Zhou; I Mikami; H Li; A Yagui-Beltran; A Beltran; M Johansson; L M Coussens; G Clement; Y Shi; F Zhang; K Koizumi; K Shimizu; D Jablons; B He
Journal:  Oncogene       Date:  2010-08-09       Impact factor: 9.867

7.  Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.

Authors:  Jimmie Colon; Md Riyaz Basha; Rafael Madero-Visbal; Santhi Konduri; Cheryl H Baker; Luis J Herrera; Stephen Safe; David Sheikh-Hamad; Ala Abudayyeh; Beatrice Alvarado; Maen Abdelrahim
Journal:  Invest New Drugs       Date:  2009-10-23       Impact factor: 3.850

8.  Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells.

Authors:  G Hodge; J Barnawi; C Jurisevic; D Moffat; M Holmes; P N Reynolds; H Jersmann; S Hodge
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

9.  Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.

Authors:  Ali Mallakin; Takayuki Sugiyama; Pankaj Taneja; Lauren A Matise; Donna P Frazier; Mayur Choudhary; Gregory A Hawkins; Ralph B D'Agostino; Mark C Willingham; Kazushi Inoue
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

10.  HLungDB: an integrated database of human lung cancer research.

Authors:  Lishan Wang; Yuanyuan Xiong; Yihua Sun; Zhaoyuan Fang; Li Li; Hongbin Ji; Tieliu Shi
Journal:  Nucleic Acids Res       Date:  2009-11-09       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.